Related Experiment Video
Updated: Mar 16, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
18.8K
Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications
Ilinca Popp1, Anca Ligia Grosu1, Gabriele Niedermann1
1Department of Radiation Oncology, University Medical Center Freiburg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.
Summary
Stereotactic body radiation therapy (SBRT) can activate anti-tumor immunity, potentially enhancing cancer treatment. Combining SBRT with immunotherapy may increase these abscopal effects, warranting further research.
Area of Science:
- Radiation Oncology
- Immunology
- Cancer Therapy
Background:
- Stereotactic body radiation therapy (SBRT) is a non-invasive treatment for malignant tumors.
- Abscopal effects, or out-of-field immune responses, suggest SBRT can activate anti-tumor immunity.
Purpose of the Study:
- To review evidence for SBRT-induced immune modulation, alone and with immunotherapy.
- To explore the potential of SBRT and immunotherapy combinations for enhanced anti-tumor responses.
Main Methods:
- Review of preclinical research and clinical observations on SBRT and immune responses.
- Analysis of studies investigating SBRT in combination with immunotherapies, including immune checkpoint blockers.
Main Results:
- SBRT alone can induce immune changes, but clinical survival benefits from immune modulation are rare.
- Preclinical studies show SBRT alters the balance between anti-tumor immunity and immunosuppression.
- Combining SBRT with immunotherapy, especially immune checkpoint blockers, shows potential for increased abscopal effects.
Conclusions:
- SBRT has the potential to modulate anti-tumor immunity.
- Further research is needed to understand SBRT-immunity interactions for clinical benefit.
- Combination therapy with SBRT and immunotherapy holds promise for improving cancer treatment outcomes.
